“The impact of tralokinumab on quality of life and school in patients aged 12-17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s139. doi:10.25251/skin.7.supp.139.